Introduction to Gubra

Introduction to Gubra - CEO Henrik Blou and CFO Kristian Borbos presenting the company.

Gubra consists of two business areas - CRO business that offers specialized pre-clinical contract research and development services for the pharmaceutical and biotechnology industry and the D&P business that offers discovery, design and development of peptidebased drug candidates with the aim of entering partnerships with pharmaceutical or biotechnology companies. The CRO business is generating topline and cashflow, The D&P is more a traditional Biotech business with milestones and cashburn. Good synergies between the two areas. Besides these two areas Gubra allocates 10% of pre-tax to Gubra Green with a true ESG footprint.

Listen to the presentation here: https://www.inderes.dk/videos/gubra-company-introduction 

Disclaimer:

HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility agreement.